Abstract:Quercetin decreases ACE2, TMPRSS2, and ADAM17 in human Calu‐3 lung cells cultured at an air–liquid interface (Calu‐3‐ALI) but has no effect on severe acute respiratory syndrome coronavirus 2 infection. Created with BioRender.com. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) binds to angiotensin‐converting enzyme 2 (ACE2) on host cells, via its spike protein, and transmembrane protease, serine 2 (TMPRSS2) cleaves the spike‐ACE2 complex to facilitate virus entry. As rate‐limiting steps for virus entry, modulation of ACE2 and/or TMPRSS2 may decrease SARS‐CoV‐2 infectivity and COVID‐19 severity. In silico modeling suggested the natural bioactive flavonoid quercetin can bind to ACE2 and a recent randomized clinical trial demonstrated that oral supplementation with quercetin increased COVID‐19 recovery. A range of cultured human cells were assessed for co‐expression of ACE2 and TMPRSS2. Immortalized Calu‐3 lung cells, cultured and matured at an air–liquid interface (Calu‐3‐ALIs), were established as the most appropriate. Primary bronchial epithelial cells (PBECs) were obtained from healthy adult males (N = 6) and cultured under submerged conditions to corroborate the outcomes. Upon maturation or reaching 80% confluence, respectively, the Calu‐3‐ALIs and PBECs were treated with quercetin, and mRNA and protein expression were assessed by droplet digital PCR and ELISA, respectively. SARS‐CoV‐2 infectivity, and the effects of pre‐ and co‐treatment with quercetin, was assessed by median tissue culture infectious dose assay. Quercetin dose‐dependently decreased ACE2 and TMPRSS2 mRNA and protein in both Calu‐3‐ALIs and PBECs after 4 h, while TMPRSS2 remained suppressed in response to prolonged treatment with lower doses (twice daily for 3 days). Quercetin also acutely decreased ADAM17 mRNA, but not ACE, in Calu‐3‐ALIs, and this warrants further investigation. Calu‐3‐ALIs, but not PBECs, were successfully infected with SARS‐CoV‐2; however, quercetin had no antiviral effect, neither directly nor indirectly through downregulation of ACE2 and TMPRSS2. Calu‐3‐ALIs were reaffirmed to be an optimal cell model for research into the regulation of ACE2 and TMPRSS2, without the need for prior genetic modification, and will prove valuable in future coronavirus and respiratory infectious disease work. However, our data demonstrate that a significant decrease in the expression of ACE2 and TMPRSS2 by a promising prophylactic candidate may not translate to infection prevention.

GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies

GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2

The Inhibiting Effect of GB-2, (+)-Catechin, Theaflavin, and Theaflavin 3-Gallate on Interaction between ACE2 and SARS-CoV-2 EG.5.1 and HV.1 Variants

Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor

Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations

Anisomeles indica Extracts and Their Constituents Suppress the Protein Expression of ACE2 and TMPRSS2 In Vivo and In Vitro

Repurposing Astragalus Polysaccharide PG2 for Inhibiting ACE2 and SARS-CoV-2 Spike Syncytial Formation and Anti-Inflammatory Effects

Distinct Mechanisms for TMPRSS2 Expression Explain Organ-Specific Inhibition of SARS-CoV-2 Infection by Enzalutamide

Study on the potential of Sanghuangporus sanghuang and its components as COVID-19 spike protein receptor binding domain inhibitors

Transcriptional regulation and small compound targeting of ACE2 in lung epithelial cells

Synergistic inhibition effects of andrographolide and baicalin on coronavirus mechanisms by downregulation of ACE2 protein level

Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo

Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study

The flavonoid quercetin decreases ACE2 and TMPRSS2 expression but not SARS‐CoV‐2 infection in cultured human lung cells

Anti-SARS-CoV-2 Viral Activity of Sweet Potato Trypsin Inhibitor via Downregulation of TMPRSS2 Activity and ACE2 Expression In Vitro and In Vivo

1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection

ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker

Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay

Imatinib (STI571) Inhibits the Expression of Angiotensin-Converting Enzyme 2 and Cell Entry of the SARS-CoV-2-Derived Pseudotyped Viral Particles

Hesperidin Is a Potential Inhibitor against SARS-CoV-2 Infection

“Molecular Masks” for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry